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Recognition of overlapping molecular signaling activated by a chemical trigger of cancer
and neurodegeneration is new, but the path to this discovery has been long and potholed.
Six conferences (1962–1972) examined the puzzling neurotoxic and carcinogenic proper-
ties of a then-novel toxin [cycasin: methylazoxymethanol (MAM)-β-D-glucoside] in cycad
plants used traditionally for food and medicine on Guam where a complex neurodegener-
ative disease plagued the indigenous population. Affected families showed combinations
of amyotrophic lateral sclerosis (ALS), parkinsonism (P), and/or a dementia (D) akin to
Alzheimer’s disease (AD). Modernization saw declining disease rates on Guam and remark-
able changes in clinical phenotype (ALS was replaced by P-D and then by D) and in two
genetically distinct ALS-PDC-affected populations (Kii-Japan, West Papua-Indonesia) that
used cycad seed medicinally. MAM forms DNA lesions – repaired by O6-methylguanine
methyltransferase (MGMT) – that perturb mouse brain development and induce malignant
tumors in peripheral organs. The brains of young adult MGMT-deficient mice given a sin-
gle dose of MAM show DNA lesion-linked changes in cell-signaling pathways associated
with miRNA-1, which is implicated in colon, liver, and prostate cancers, and in neuro-
logical disease, notably AD. MAM is metabolized to formaldehyde, a human carcinogen.
Formaldehyde-responsive miRNAs predicted to modulate MAM-associated genes in the
brains of MGMT-deficient mice include miR-17-5p and miR-18d, which regulate genes
involved in tumor suppression, DNA repair, amyloid deposition, and neurotransmission.
These findings marry cycad-associated ALS-PDC with colon, liver, and prostate cancer; they
also add to evidence linking changes in microRNA status both to ALS, AD, and parkinsonism,
and to cancer initiation and progression.
Keywords: ALS-PDC, Alzheimer disease, amyotrophic lateral sclerosis, methylazoxymethanol, BMAA,
formaldehyde, DNA damage, colon cancer
INTRODUCTION
Non-coding RNAs in the form of microRNAs (miRNAs) form a
class of hundreds of short, non-coding RNA regulatory molecules
that base pair with multiple target mRNAs to down-regulate gene
expression by mechanisms ranging from translational inhibition
to mRNA degradation (O’Carroll and Schaefer, 2012). miRNAs
arise from long RNA hairpin transcripts that are processed in the
cell nucleus by the Drosha microprocessor complex and then, in
the cytoplasm, by Dicer, an endoribonuclease in the RNase III
family. One of the two complementary short RNA molecules so
formed is integrated into the RISC complex, a ribonucleoprotein
complex containing members of the Argonaute (Ago) family of
endonucleases, the activity of which is directed against mRNA
strands that are complementary to their bound miRNA fragment.
After integration into the active RISC complex, miRNAs bind to
imperfect complementary sites within the 3′ untranslated regions
(UTRs) of their mRNA targets and thereby effect repression of
gene expression.
MicroRNAs are heavily represented in the nervous system
where they take part in most if not all cell processes, including
during development and in adult health and disease. This method
of post-transcriptional gene modulation plays an important role
in nerve cell differentiation and neuronal function (Vo et al., 2005;
Schratt et al., 2006; Leucht et al., 2008; Yu et al., 2008; Siegel et al.,
2009; Yoo et al., 2009; Feng and Feng, 2011; Schouten et al., 2012),
and changes in expression of specific miRNAs have been found
in neurodegenerative diseases (Cogswell et al., 2008; Packer et al.,
2008; Haramati et al., 2010; Gascon and Gao, 2012). The functional
relevance of miRNAs in brain disease is illustrated by miR-134,
activity of which is upregulated in the brain of animals with sta-
tus epilepticus and, when silenced, reduces hippocampal dendritic
spine density and makes mice refractory to seizures and resulting
hippocampal damage (Jimenez-Mateos et al., 2012). miRNAs are
also important, but perhaps not essential, for tumor growth and
survival, in thatDicer1-deficient sarcoma cells lacking miRNAs are
tumorigenic (Ravi et al., 2012).
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MicroRNAs have elicited considerable interest among those
seeking to understand the pathogenesis, diagnosis, and treatment
of key neurodegenerative disorders, notably Alzheimer’s disease
(AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS). However, the sum total of publications on these subjects
(∼125) pales in comparison with those associated with cancer
(∼6700), including colon cancer (∼300), the specific subject that
links cancer with neurodegenerative disease in this review. The
neurodegenerative disease addressed here, namely western Pacific
ALS-parkinsonism-dementia complex (ALS-PDC), combines in
single patients the clinical and neuropathological features of the
key neurodegenerative disorders ALS, atypical parkinsonism, and
AD (illustrated videographically at: http://vimeo.com/1621281).
While there are several types of dominantly inherited cases of
ALS, PD, and AD with specific gene mutations, these represent
a minority (∼10%) since most of these disorders occur sporad-
ically, indicating the operation of environmental factors in the
presence or absence of genetic susceptibilities. Evidence indicates
that the etiology of ALS-PDC is predominantly, if not exclu-
sively, environmental in origin. In particular, the disease has been
repeatedly associated with early life exposure via traditional food
and/or medicine to naturally occurring chemical constituents of
cycad plants (Cycas spp.; see: http://vimeo.com/1621281), includ-
ing methylazoxymethanol-β-d-glucoside (cycasin, the principal
toxin), a developmental neurotoxin, mutagen, and carcinogen, and
the non-proteogenic amino acid β-N -methylamino-l-alanine (l-
BMAA, a minor component present in free and bound form). Both
methylazoxymethanol (MAM) and l-BMAA are metabolized to
formaldehyde, a human carcinogen with neurotoxic potential
(Kisby and Spencer, 2011). This review examines how MAM and
formaldehyde modulate miRNA function in brain and other tis-
sues and the relationship between the neurotoxic and carcinogenic
properties of MAM at the systems-biology level. We begin with a
description of the relationship of ALS-PDC with ALS, PD, and
AD, and a summary of the function and known involvement of
miRNAs in development and neurodegenerative diseases, and how
they overlap with cancer.
NEURODEGENERATION AND CANCER
Neurodegenerative disorders, like cancer, are progressive fatal dis-
eases that surface clinically long after disease initiation and cellular
pathology have progressed. While cancers develop from cycling
cells that undergo uncontrolled cell division and migration, neu-
rodegenerative diseases arise from the dysfunction and loss of
non-cycling cells, specifically post-mitotic neurons in the brain
and spinal cord. Many such neurodegenerative disorders are asso-
ciated with deposition of modified, abnormally folded proteins in
the neuronal cytoplasm or extracellular spaces between brain cells.
The intracellular protein accumulations (“bodies”) were described
by early histologists and frequently bear their names (Bunina,
Lewy, etc.), while the amyloid precursor protein is cleaved by a
γ secretase to form amyloid, which accumulates in extracellular
plaques.
The degeneration of motor neurons in brain and spinal cord
results in the clinical picture of ALS (motor neuron disease), which
is characterized by progressive limb and bulbar weakness, muscle
denervation, and atrophy. Spinal and hypoglossal motor neurons
develop Bunina bodies, which are closely associated with deposi-
tion of cytoplasmic TAR DNA-binding protein 43 (TDP-43). PD is
characterized by neuronal deposition of α-synuclein in Lewy bod-
ies and degeneration of nerve cells in the substantia nigra that are
responsible for the quality of voluntary movement. Those with PD
develop a resting tremor, limb rigidity, shuffling gait, and masked
facies, often accompanied by cognitive changes. Progressive loss
of cognitive function is the hallmark of AD, which is featured
by the intracellular accumulation of tau protein in neurofibril-
lary tangles and the extracellular deposition of β-amyloid protein
clusters in neuritic and senile plaques, the loss of hippocampal
neurons, and brain atrophy. Genetic ablation of Dicer in adult
forebrain neurons results in abnormal tau hyperphosphorylation
and neurodegeneration (Hébert et al., 2010).
Western Pacific ALS-PDC is a polyproteinopathy (dominated
by pathological tau isoforms; McGeer and Steele, 2011), the var-
ious clinical forms of this disease differentially expressing most
of the neuropathological features of ALS, PD, and AD. When the
disease was discovered on Guam in the 1940s, the dominant clin-
ical form was ALS among relatively young people but, as rates
declined, atypical parkinsonism among the middle-aged became
prominent, only later to be displaced by an AD-like dementia
in the elderly. Neuropathological examination demonstrated a
single nosologic entity, with pathological emphasis on the areas
corresponding to the nature of the clinical disease. Overall, the
changing expression, increasing age of onset, and overall decline
in ALS-PDC prevalence over the past 70 years, is consistent with a
disappearing environmental agent as the principal cause. A similar
longitudinal trend of neurodegenerative disease has occurred for
ALS-PDC among Japanese living in the Kii peninsula of Honshu
Island and among the Auyu and Jaqai linguistic groups of West
Papua, Indonesia. The common feature among these three genet-
ically distinct populations is the traditional use of cycad seed for
medicine and, on Guam, for food and medicine. Rates of neurode-
generative disease have declined in Guam, Japan, and Indonesia
in association with the slow disappearance of these traditional
practices. Environmental factors therefore appear to dominate the
etiology of western Pacific ALS-PDC, and there is no compelling
evidence for the participation of either inherited factors or genetic
predisposition in the three affected populations. The foregoing has
been reviewed recently (Kisby and Spencer, 2011).
Unknown environmental factors are thought to have a signif-
icant etiologic role in a majority of cases of ALS, PD, and AD
but, in addition, there are also hereditable genetic abnormalities
in a small percentage of cases in each of these neurodegenerative
diseases. In some ALS cases, the mutant human gene has been
inserted into mice, which subsequently express the clinical and
pathological features of the human disease, including the cytoplas-
mic deposition of TDP-43. This protein promotes the production
of a subset of precursor miRNAs through interaction with the
Drosha microprocessor complex and by binding directly with the
relevant primary miRNAs. Cytoplasmic TDP-43 interacts with the
Dicer complex and promotes the processing of some of the pre-
cursor miRNAs by binding to their terminal loops. Since neuronal
outgrowth requires the involvement of TDP-43 in miRNA biogen-
esis, aberrant forms of TDP-43 that precipitate in the cytoplasm
may trigger events leading to the motor neuron degeneration that
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characterizes ALS (Kawahara, 2010; Kawahara and Mieda-Sato,
2012). While the continuous presence of the mutant gene explains
how cellular dysfunction advances to trigger a progressive and
eventually fatal disease, whether and how an environmental toxin
might have a comparable action in ALS-PDC is an open question
that has been examined (Kisby and Spencer, 2011).
The association of ALS-PDC with cycad exposure, and in par-
ticular with the genotoxin, carcinogen, and neurotoxin MAM, has
for decades led to the suspicion that cancer and neurodegenera-
tive diseases may be related disorders (Whiting, 1988), mechanistic
evidence for which was presented recently and is discussed later
in this paper (Kisby and Spencer, 2011; Kisby et al., 2011a). Other
evidence for overlapping molecular mechanisms in cancer and
neurodegenerative diseases has been summarized by Caricasole
et al. (2005), Staropoli (2008), and de Strooper (2010). For exam-
ple, overactivation of the Wnt-β-catenin signaling pathway is seen
in several types of human malignancy, while comparable changes
in this signaling pathway in the brain are linked to neurodegenera-
tion (Caricasole et al., 2005). In the case of the gene (ATM ) for the
inherited autosomal recessive disorder ataxia telangiectasia, DNA-
damage-related loss-of-function mutations trigger both cerebellar
neuronal degeneration and increase the susceptibility to neoangio-
genesis and tumor progression in breast cancer (Gatti et al., 1988;
Cuatrecasas et al., 2006). A second example is Down syndrome, in
which there is a high incidence of leukemia or lymphoma as well
as the development of AD-like neuropathology in early adulthood
(Levine et al., 2009). A third is provided by the gene PARKIN,
where loss-of-function mutations lead to early-onset PD (Kumar
et al., 2011). PARK-2 is also a candidate tumor-suppressor gene
that is downregulated in several tumor types, including uterine
carcinoma (Veeriah et al., 2010; Mehdi et al., 2011). Others have
noted a significant association between melanoma and both ALS
and PD mortality (Baade et al., 2007).
MicroRNAs have been implicated in the initiation and progres-
sion of both malignant tumors and neurodegenerative disorders
by either regulating common pathways associated with both dis-
eases or by targeting genes specific to each disease (Cooper et al.,
2009; Du and Pertsemlidis, 2011). The best example is the so-
called Alzheimer precursor protein (APP). While an increased
expression of APP is clearly established in AD (Podlisny et al.,
1987; Rovelet-Lecrux et al., 2006; Theuns et al., 2006; LaFerla et al.,
2007), APP is also overexpressed in numerous cancers, including
colorectal cancer (Hansel et al., 2003; Ko et al., 2007; Arvidsson
et al., 2008; Krause et al., 2008). In particular, miR-17-5p (dis-
cussed later), mIR-20a, and miR-106b reduce endogenous APP
expression in vitro (Hébert et al., 2009). A single miRNA may also
be involved in neurodegeneration and cancer by regulating sepa-
rate pathways (Du and Pertsemlidis,2011). For example,miR-133b
is downregulated in esophageal, lung and colon cancers (Bandrés
et al., 2006; Crawford et al., 2009; Hu et al., 2010; Kano et al., 2010)
and, through different pathways, may play a role in PD (Kim et al.,
2007). Similarly, by acting via different pathways, miR-124a has
been implicated in both tumorigenesis and PD (Lujambio and
Esteller, 2007; Simunovic et al., 2009). Members of the miR-29
family of miRNAs target multiple proteins involved in both neu-
rodegenerative diseases and cancers by regulating common path-
ways and those specific for each condition (Du and Pertsemlidis,
2011). Downregulation of the miR-9 gene changes the stoichiome-
try of axonal neurofilaments (upregulates a gene coding for a heavy
neurofilament subunit) in a mouse model of human spinal muscu-
lar atrophy characterized by anterior horn sclerosis, aberrant end
plate architecture, and myofiber atrophy with signs of denervation
(Haramati et al., 2010), while it is overexpressed in several cancer
forms, including brain tumors, hepatocellular carcinomas (HCC),
breast cancer, and Hodgkin lymphoma. Inhibition of miR-9 leads
to derepression of Dicer (Leucci et al., 2012); it suppresses matrix
metalloproteinase (MMP)-14 expression via binding to a site in the
3′-UTR, thus inhibiting the invasion, metastasis, and angiogenesis
of neuroblastoma (Zhang et al., 2012a). miR-132 is implicated in
prostate and pancreatic tumorigenesis (Park et al., 2011; Zhang
et al., 2011; Formosa et al., 2012) and downregulated in progres-
sive supranuclear palsy, a neurodegenerative tauopathy related
to the atypical parkinsonism of ALS-PDC (Smith et al., 2011).
Down-regulation of the tumor suppressors miR-34b and miR-34c
has been described in PD and linked to decreased expression of
parkin protein (Minones-Moyano et al., 2011). MiR-7, which neg-
atively controls the function of α-synuclein mRNA (Mouradian,
2012), also serves as an anti-metastatic miRNA in gastric cancer
by targeting Insulin-like Growth Factor-1 (IGF-1) (Zhao et al.,
2012). In sum, therefore, individual miRNAs may be differentially
expressed in both cancers and neurodegenerative disorders; the
following addresses the possible relationship between miRNAs,
MAM, cancer, and ALS-PDC.
MAM, DNA DAMAGE/REPAIR, AND LINK WITH ALS-PDC
The discovery in the 1960s of cycasin and its genotoxic aglycone
MAM arose from studies of ALS among Guam Chamorros who
were found to use the neurotoxic seed of cycad plants (Cycas
micronesica) for food and topical medicine (Whiting, 1988). Med-
icinal use of cycad seed was later discovered in the two other
ALS-PDC hotspots, namely Kii Pensinsula of Japan and the Auyu
and Jaqai linguistic groups of West Papua, Indonesia (Spencer
et al., 1987a,b, 2005). Epidemiological studies on Guam showed
an association between neurodegenerative disease and prior use
of washed cycad seed to prepare flour for food (Borenstein et al.,
2007). In particular, the residual content of cycasin in cycad flour
was very strongly correlated with the risk for both ALS and P-D
among Chamorros (Kisby et al., 1992a; Román et al., 1995; Zhang
et al., 1996).
Methylazoxymethanol is a potent alkylating agent that spon-
taneously breaks down into reactive molecules, notably methyl-
diazonium ions and carbon-centered free radicals that methylate
nucleic acids at the O6-, N7-, and C8 positions of guanine (Mat-
sumoto and Higa, 1966; Shank and Magee, 1967; Nagata and
Matsumoto, 1969; Nagasawa et al., 1972; Kisby et al., 1995). MAM-
induced DNA damage accounts for the long-recognized dual
carcinogenic and neurotoxic properties of cycasin/MAM. Below,
we show that DNA damage in the form of O6-methylguanosine
is specifically associated with the ability of cycasin/MAM to dis-
rupt murine neurodevelopment (Kisby et al., 1999, 2009) and that
failure to repair this type of DNA lesion by O6-methylguanine
methyltransferase (MGMT) activates cellular pathways in the
rodent brain that are associated with both cancer and human neu-
rodegenerative disease (Kisby et al., 2011a). While various types
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of DNA lesions, especially those associated with oxidative dam-
age, are linked with neurodegenerative diseases (ALS, PD, AD, and
ATM; Martin, 2008), the association with O6-mG lesions has not
been described by others. Emerging evidence indicates that DNA
damage results in the differential activation of miRNAs (Wan et al.,
2011; Han et al., 2012). It appears that varying amounts of DNA
damage lead to the activation of unique as well as common sets of
miRNAs, suggesting that the nature and intensity of DNA damage
are key factors. Although several DNA damage-responsive targets
have been identified, many remain to be discovered, including
those activated in the brain by environmental agents that induce
DNA damage.
SYSTEMS BIOLOGY OF MAM IN CANCER
In addition to its neurotoxic properties and its possible etio-
logic role in ALS-PDC, MAM is an established hepatotoxin and
experimental carcinogen (Adamson, 1989). Rodents that have
been chronically treated with the MAM precursor azoxymethane
(AOM) are widely used as models for investigating the pathogen-
esis and chemoprevention of human colon carcinoma (Rosenberg
et al., 2009). A remarkable number of miRNAs exhibits differential
expression in colon cancer tissues; these miRNAs alter cell prolif-
eration, apoptosis, and metastasis through their interactions with
intracellular signaling networks (Schetter and Harris, 2011; Wu
et al., 2011). For example let-7, miR-18a and miR-143 are strongly
linked to KRAS knockdown and activation of the epidermal
growth factor receptor-mitogen activated protein kinase (EGFR-
MAPK) pathway, whereas miR-21 and miR-126 are associated with
augmentation or inactivation of the phosphatidylinositol-3-kinase
pathway (Aslam et al., 2012). Activation of these downstream
pathways results in autonomous tumor cell growth, increased cell
survival, and initiation of angiogenesis.
The molecular mechanisms underlying the formation of colon
tumors in the AOM rodent model of intestinal adenocarcinoma
are solely triggered by MAM (the cytochrome P4502E1-mediated
metabolite of AOM; Nigro, 1985; Chen and Huang, 2009). In this
rodent model, the expression of 27 miRNAs is significantly (>6-
fold) increased (e.g., miR-1, miR-34a, 132, 223, and 224), while
that of 19 miRNAs is reduced (<0.49-fold; e.g., miR-192, 194, 215,
and 375) in the colon tumors (Davidson et al., 2009). Epidermal
growth factor receptors (EGFR) suppress the tumor suppressors
miR-143 and miR-145, which coordinately control multiple tar-
gets of downstream cell-signaling pathways (i.e., K-Ras or MYC,
cdk6, E2F3, and G1/S-specific cyclin-D2 or CCND2) in the AOM
rodent model (Zhu et al., 2011). These studies indicate that AOM
induces global changes in the expression of miRNAs in colonic
tumors. MAM-induced mutation of KRAS (i.e., transversion from
G:C to A:T at codon 12 derived from O6-mG lesions) activates
this pathway and the downstream MAPK and phosphoinositide 3-
kinase/Akt (PI3K/Akt) mediators, indicating that MAM perturbs
gene expression in these pathways by a DNA damage-dependent
mechanism. The activation of these same pathways by associated
miRNAs in human colon cancer and the AOM animal model sug-
gests that the DNA damage produced by MAM might perturb
cell-signaling pathways by altering the biogenesis of miRNAs. In
support, miR-1 is altered in the colon of AOM-treated rats (David-
son et al., 2009) and was a prominent hub among the 362 genes
that were differentially expressed in the brain of Mgmt−/− mice
after systemic administration of MAM (Kisby et al., 2011a).
SYSTEMS BIOLOGY OF MAM IN BRAIN
Developmental neurotoxicity of MAM
MicroRNAs play an important role in normal development of the
brain, where they dictate neuronal cell identity, neurite growth,
synaptic development, and neuronal plasticity (Wheeler et al.,
2006; Feng and Feng, 2011; Olde Loohuis et al., 2012), and in
neurodevelopmental disorders (Singh, 2007; Chang et al., 2009).
Wnt1-Cre-mediated loss of Dicer, the key enzyme for miRNA
biosynthesis, results in reduced expression of β-catenin together
with malformation of the midbrain and cerebellum, and failure
of neural crest and dopaminergic differentiation (Liu et al., 2011).
Deficiency of Dicer is associated with progressive loss of miRNAs,
followed by cerebellar degeneration and development of ataxia
(Schaefer et al., 2007). Dicer also appears to be a target of several
environmental mutagens resulting in the interference of miRNA
maturation (Ligorio et al., 2011). The latter studies suggest that
environmental agents that damage DNA might indirectly alter
brain development by perturbing the maturation of miRNAs.
Although the involvement of miRNAs has yet to be defined, the
cerebellum is reproducibly perturbed when MAM or its glucoside
cycasin is administered to rodents. MAM kills or arrests neu-
roblasts undergoing mitosis. Rodents treated with MAM acetate
in utero or within days of birth show strikingly abnormal develop-
ment of the cerebellum associated with partial destruction of the
external granular layer (Hirono and Shibuya, 1967; Shimada and
Langman, 1970; Jones and Gardner, 1976; Lovell and Jones, 1980).
Apoptotic cells in the external granular cell layer appear 24 h after
MAM treatment, peak at 48 h and decrease at 72 h (Gobe, 1994;
Lafarga et al., 1997). Pregnant rats fed crude meal containing 3%
cycasin have produced litters free of brain malformations but with
an increased propensity for glial malignancy in adult life (Lac-
queur and Spatz, 1973). Rats exposed in utero [gestational day 15
(GD15) or less] to MAM or MAM acetate show microcephaly, and
some develop endocrine adenomas, oligodendromas, and schwan-
nomas, or tumors at peripheral sites (Lacqueur and Spatz, 1973).
Exposure at later stages of embryonic brain development (i.e.,
GD17) produces an animal model that consistently displays neu-
rochemical and neuropathological changes and associated behav-
ioral characteristics similar to those observed in patients with
schizophrenia (Featherstone et al., 2007; Lodge and Grace, 2009;
Chin et al., 2011; Hradetzky et al., 2012). Calcium-signaling, glu-
tamate receptor signaling, and long-term potentiation were the
predominant cell-signaling pathways perturbed in the hippocam-
pus of rats treated on GD17 with MAM (Lodge and Grace, 2009;
Hradetzky et al., 2012). Glutamate receptor signaling and RNA
post-transcriptional modification, molecular transport and RNA
trafficking,were also among the top molecular networks perturbed
in the prefrontal cortex of rats exposed on GD17 to MAM (Merker
et al., 2009).
The Kisby laboratory examined the relationship between
MAM-induced DNA damage (O6-methylguanosine) and the
development of the brain of wild-type neonatal mice and
mutant mice that either lacked the O6-mG DNA-repair enzyme
(Mgmt−/−) or contained genes coding for both human and
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murine MGMT and thus overexpressed the DNA-repair enzyme
(MgmtTg+; Figure 1). In wild-type mice, MAM reduced the den-
sity of neurons in the granule cell layer and disrupted the orga-
nization of the Purkinje cell layer. Changes in granule cell and
folia development were significantly greater in Mgmt−/− mice
treated with MAM. By contrast, cerebellar morphology was better
preserved in MGMTTg+ mice treated with MAM. Thus, MGMT
protects immature neurons from MAM-induced injury through a
DNA-damage-mediated mechanism (Kisby et al., 2009).
There were 251 genes differentially expressed in the cerebellum
of neonatal MAM-treated Mgmt−/− mice when compared with
the corresponding cerebellum of MAM-treated MgmtTg+ animals
(G. E. Kisby, unpublished data). Glutamate and γ-aminobutyric
acid neurotransmission, chromatin remodeling, and neuronal and
glial development, were the predominant cellular systems per-
turbed by MAM in the cerebellum of Mgmt−/− mice; together,
they explain the MAM-induced changes in cerebellar development
and motor function (Kisby et al., 2009). The pronounced effect of
MAM on both fetal and neonatal glutamatergic neurotransmis-
sion and neural development, which are altered in schizophrenia
(Kantrowitz and Javitt, 2012), suggests the developing brain is
especially sensitive to DNA damage. Since the processing of mRNA
and the chromatin remodeling machinery were also key targets
of MAM in the fetal and neonatal brain, these studies suggest
that MAM alters the development of neurons by a mechanism
involving both DNA damage and epigenetic mechanisms.
Adult brain response to MAM
The adult human brain has a low or absent capacity to repair
alkylation-induced DNA damage (Silber et al., 1996; Bobola et al.,
2007), with implications for long-term survival and eventual
degeneration of nerve cells (Robison and Bradley, 1984). We
tested the hypothesis that the DNA-damaging properties of MAM,
which are mutagenic and tumorigenic in cycling cells of the
colon epithelium (Rosenberg et al., 2009), activate molecular net-
works associated with the degeneration of post-mitotic neurons in
human neurodegenerative disease. To address this hypothesis, we
compared the relationship between MAM-induced DNA damage
(O6-methylguanosine) and gene expression patterns in the brains
of adult wild-type and Mgmt−/− mice. Two separate laboratories
treated groups of mice with a single systemic dose of MAM, and
the combined data were mined for common brain transcriptional
profiles. A third laboratory conducted blinded analyses of brain
O6-methylguanosine levels. Signaling pathways associated with
cancer and human neurodegenerative disease were activated in
the mature mouse brain as the result of unrepaired MAM-induced
DNA damage (Kisby et al., 2011a).
A computational approach was used to determine which
miRNAs are likely to regulate MAM-modulated gene expres-
sion in the adult mouse brain. The most significant mol-
ecular networks derived from 362 MAM-triggered, differen-
tially expressed genes revealed hubs involving NF-κB (nuclear
factor of kappa light polypeptide gene enhancer in B-cells),
FIGURE 1 | Cytoarchitecture of the cerebellum of wild-type and
DNA-repair mutant mice treated with MAM acetate. Light micrographs of
representative areas from cresyl violet-stained parasagittal sections (10µm)
of the postnatal 22-day-old cerebellum from C57BL/6J (wild), Mgmt−/−, or
MgmtTg+ treated on postnatal day 3 with a single injection of saline (left
panels) or MAM 325µmol, s.c. (center panels). Higher magnification of the
cerebellum from wild-type or DNA repair mutant mice treated with MAM
(right panels). MAML, low magnification (3.85×), MAMH, high magnification
(77×), f, folia. Arrows indicate disorganization of Purkinje cell layer and stars
denote reduced density of neurons in granule cell layer. Mgmt : gene coding
for O6-mG-methyltransferase (MGMT), which is knocked out in Mgmt−/− and
overexpressed in MgmtTg+ mice (modified from Kisby et al., 2009).
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calcium-binding proteins (i.e., calcineurin, calmodulin), brain-
derived neurotrophic factor (BDNF), glutamate receptors N -
methyl-d-aspartate (NMDA), and α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA), cyclic AMP response element-
binding factor (CREB), and miR-1 (Kisby et al., 2011a). Each of
these gene hubs was computationally analyzed to identify poten-
tial regulating miRNAs. Specifically, this analysis required the use
of the miRNA database (miRDB, www.mirdb.org) to predict miR-
NAs with seed regions that match the base pair sequences of the
mRNAs within their 3′-UTRs. miRNAs that controlled more than
one mRNA are listed in Table 1. These data demonstrate that mul-
tiple miRNAs likely regulate the MAM-generated hubs, a finding
that has been shown by others (Nohata et al., 2012).
MiR-134 has an important role in the brain, where it is essential
for activity-dependent dendritic outgrowth, nerve growth cone
guidance, and size of dendritic spines of hippocampal neurons
(Schratt et al., 2006; Khudayberdiev et al., 2009; Han et al., 2011).
Silencing of miR-134 expression reduces dendritic spine density
and renders mice refractory to seizures and hippocampal injury
caused by status epilepticus (Jimenez-Mateos et al., 2012). MiR-134
is also a powerful inducer of pluripotent stem cell differentia-
tion and functions as a regulator of cell proliferation, apoptosis,
and migration during lung development (Zhang et al., 2012c).
The expression of miR-134 is reduced in gastrointestinal stromal
tumors (Haller et al., 2010). MiR-204 is proposed to play critical
roles in the development and progression of malignant peripheral
nerve sheath tumors (Gong et al., 2012); it also suppresses tumor
cell growth of renal clear cell tumors (Mikhaylova et al., 2012).
Downregulation of miR-204 activates Ras in gastric cancer cells
(Lam et al., 2011) and reduces lung metastasis of squamous cell
carcinomas of the head and neck (Lee et al., 2010). Transfection of
miR-204 into human trabecular meshwork cells increased levels of
apoptosis, decreased viability, and increased the accumulation of
oxidized proteins, decreased induction of endoplasmic reticulum
stress response markers, and reduced expression of inflamma-
tory mediators (Li et al., 2011). MiR-211 has a binding site for
angiopoietin-1, which is a vascular strengthening factor during
vascular development and a protective factor for pathological vas-
cular inflammation and leakage, including brain vascular leakage
as occurs in stroke (Chen et al., 2010). MiR-211 expression pro-
motes colorectal cancer growth by down-regulating expression of
Table 1 | miRNAs predicted to regulate genes linked to MAM-induced
DNA damage (O6-methylguanosine) in the brains of MAM-treated
mice lacking the DNA-repair enzyme O6-methylguanine
methyltransferase (based on data in Figure 3 of Kisby et al., 2011a).
miRNA Gene targets
miR-134 Brain-derived neurotrophic factor (BDNF ) and cAMP
response element-binding factor (CREB)
miR-204 BDNF and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)
miR-211 BDNF and AMPA
miR-505 BDNF and AMPA
miR-590-3p BDNF and CREB
the CHD5 tumor suppressor (Cai et al., 2010). Increased miR-211
expression is linked with progression and vascular invasion of oral
carcinoma (Chang et al., 2008). MiR-211 is also implicated as a
tumor suppressor for melanoma invasion (Levy et al., 2010). MiR-
505 acts as a tumor suppressor by inhibiting proliferation and
inducing apoptosis of human breast cancer cells (Yamamoto et al.,
2011). MiR-590-3P regulates the transcription of heterogenous
nuclear ribonucleoprotein A1 (hnRNP-A1); both are dysregulated
in the blood of patients with AD but not with frontotemporal lobal
degeneration (Villa et al., 2011).
The differential response of genotypes to MAM vs. vehicle
were grouped together with the response of Mgmt−/− brains to
systemic treatment with MAM vs. vehicle, for a total of 443 non-
duplicated genes. The most significant scoring sub-network of
these MAM-differentially expressed genes (p< 10-46) contained
hubs for F-actin, NF-κB, cofilin, calcium/calmodulin-dependent
protein kinase II (CaMKII), glycogen synthase, the AMPA recep-
tor, BDNF, and miR-1. There is a large literature on miR-1, much
of which is focused on cardiac muscle function (Mishima et al.,
2007). MiR-1 is present in nerve cells, at least in the peripheral
nervous system (Bastian et al., 2011), and blood miR-1 expres-
sion has been used to distinguish normal subjects from patients
with PD (Margis et al., 2011). MiR-1 is also involved in late-stage
cartilage cell differentiation (Sumiyoshi et al., 2010). In prostate
gland cells, miR-1 is a candidate tumor suppressor and is fre-
quently downregulated in various types of cancer (Hudson et al.,
2012). Available evidence suggests that miR-1 alters the cellular
organization of F-actin, thereby inhibiting filopodia formation,
cell motility, and tumor invasion. MiR-1 also has an oncosuppres-
sive role in breast, lung, thyroid, liver, renal, and colorectal cancer
(Datta et al., 2008; Beltran et al., 2011; Leone et al., 2011; Kawakami
et al., 2012; Kojima et al., 2012; Migliore et al., 2012), and, in the
latter, this activity is silenced by miR-1 methylation (Suzuki et al.,
2011).
Ingenuity® pathway analysis (IPA) was used to identify the most
significantly enriched biofunctions for each data set by combin-
ing significant MAM-associated brain gene expression changes at
all time-points and comparing these data. IPA analysis of the 443
gene set revealed (a) Nervous System Development and Func-
tion (64 genes), Embryonic Development (22 genes), and Organ
Development (14 genes) as the top three IPA Physiological Systems
Development and Functions perturbed by MAM, while (b) Neuro-
logical Disorders (159 genes), Psychological Disorders (75 genes),
Cancer (114 genes), and Genetic Disorders (212 genes) were the
four most significant diseases and disorders altered in the brains
of MAM-treated vs. vehicle-treated Mgmt−/− mice plus Mgmt−/−
vs. wild-type mice treated with respect to MAM vs. vehicle (Kisby
et al., 2011a).
The Kyoto Encyclopedia of Genes and Genomes (KEGG) was
used to determine the top KEGG pathways perturbed by MAM
in either wild-type or Mgmt-/-brains. Pathways involved in can-
cer (13 genes), Wnt signaling (10 genes), insulin-signaling path-
way (9 genes), purine signaling (8 genes), and MAPK signaling
(7 genes) were among the most significant. Other prominent
KEGG pathways included those involving neurotrophin signal-
ing (6 genes), focal adhesion (6 genes), chemokine signaling
(5 genes), neuroligand-receptor interaction (5 genes), and the
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calcium-signaling pathway (4 genes). Most of these pathways have
been implicated in AD and/or colon cancer (Kisby et al., 2011a)
and, in a separate recent study, some (pathways in cancer, Wnt
signaling, MAPK signaling, and calcium-pathway signaling) have
been predicted to be regulated by miR-1/miR-133A (Table 2).
METABOLISM OF MAM AND L-BMAA TO FORMALDEHYDE
Cycasin is but one of several cycad azoxyglycosides, all of which
release MAM upon enzymatic hydrolysis (Kisby et al., 1999;
Figure 2). Cycasin and the other azoxyglycosides are converted to
MAM by plant and animal β-glucosidases, whereas AOM is con-
verted to MAM by mixed function oxidases (i.e., P450 Cyp2E1).
At physiological pH, MAM is unstable and spontaneously breaks
down to formaldehyde and the methyldiazonium ion, the prox-
imate metabolite that is responsible for the facile methylation
of cellular macromolecules, including nucleic acids. Alternatively,
MAM may also undergo oxidation by Cyp2E1 or alcohol dehy-
drogenase in the liver or extrahepatic organs (e.g., brain) to form
methylazoxyformaldehyde, which under physiological conditions
spontaneously degrades to release formic acid and methyldiazo-
nium ion (Sohn et al., 2001). Since DNA alkylation was signif-
icantly greater in the colon, kidney, and lung of MAM-treated
Cyp2E1-null than wild-type mice, but reduced after similar treat-
ment with AOM (Sohn et al., 2001), the enzymatic oxidation of
MAM is not likely to be the predominant metabolic pathway in
both hepatic and extrahepatic organs.
Table 2 |Top KEGG pathways in the brains of MAM-treated mice and
associated miRNAs in human cancers.
Top MAM-associated KEGG
pathways in mouse brain
Genes Phenotype miR-1/miR-
133A-regulated
in human
cancers*
Pathways in cancer 13 CC Yes
Wnt signaling 10 AD, CC Yes
Insulin signaling 9 AD, ALS
Purine metabolism 9
Prostate cancer 8 CC
MAPK signaling 7 AD, CC Yes
Melanogenesis 6 PD? CC
Neurotrophin signaling 6 AD
Focal adhesion 6 AD, CC Yes
Chemokine signaling 5 AD Yes
Neuroactive ligand-receptor
interaction
5 AD
Calcium-signaling pathway 4 AD, CC Yes
Top brain KEGG pathways (derived from 443 MAM-modulated genes) and the
number of MAM-modulated genes and human diseases associated with each
pathway. AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; CC, colon
cancer; PD, idiopathic Parkinson’s disease (modified from Kisby et al., 2011a).The
right-hand column shows the biological processes or signaling pathways poten-
tially regulated by the miR-1/miR-133a cluster in human cancers examined by
*Nohata et al. (2012). Additional signaling pathways in Nohata and colleagues’
top 20 included those related to the glutamatergic synapse and axon guidance,
both of which are perturbed by MAM.
Whereas MAM-glycone (cycasin) is the principal toxic compo-
nent of cycad seed (4% w/w) that can damage the nervous system,
a second agent, l-BMAA, is also significant because this excitant
amino acid induces a motorsystem disease in orally fed primates
(Spencer et al., 1987c). Present in cycad seed in concentrations
10-fold lower than that of cycasin (Kisby et al., 1992a), l-BMAA
is also found in terrestrial, freshwater, and marine environments
(Banack et al., 2007; Purdie et al., 2009; Brand et al., 2010; Mondo
et al., 2012). The rapid uptake, accumulation, and release of l-
BMAA in cortical explants and synaptosomes (Kisby and Spencer,
2011) suggest that the sub-chronic neurotoxic effects of this cycad
toxin are related to unknown intracellular actions. Like MAM
and AOM, l-BMAA is metabolized to toxic species in rat tissue
slices, mouse cortical explants, and rat crude cerebral microsomes
(Kisby et al., 1992b). Kisby et al. (1992c) showed that microsomes
and mitochondria from the rodent brain metabolized both l-
BMAA and aminopyrine (standard substrate forN -demethylation
by cytochrome P450) to formaldehyde (Figure 2), enzymatic
reactions that were inhibited by the aminopyrine N -demethylase
inhibitors deprenyl, SKF525A, and piperonyl butoxide (Kisby et al.,
2011a).
FIGURE 2 | Metabolism of the cycad toxins cycasin, MAM, and
L-BMAA by plant and animal tissues. (A) Enzymatic conversion of
cycasin or azoxymethane to MAM and its degradation product
formaldehyde. (B) Enzymatic N -demethylation of L-BMAA by brain P450
to formaldehyde.
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In sum, therefore, cycad-associated l-BMAA and MAM are
both metabolized to formaldehyde; however, the role of formalde-
hyde in MAM- or l-BMAA-induced neurotoxicity, or in the
tumorigenic activity of MAM, is not known.
FORMALDEHYDE, CANCER, NEUROTOXICITY, AND
NEURODEGENERATIVE DISEASE
Formaldehyde is a skin, eye, airway, and throat irritant, and a cause
of allergic contact dermatitis. Epidemiological studies have shown
that formaldehyde exposure increases the risk of childhood and
adult asthma (Wieslander et al., 1997; Rumchev et al., 2002), acute
respiratory tract illness (Tuthill, 1984), nasopharyngeal cancer
(Vaughan et al., 2000) and, possibly, leukemia (Zhang et al., 2010a).
There is also a statistically non-significant increase in brain tumors
with “ever embalming” among formaldehyde-exposed embalmers
and funeral directors. In animal studies, strong links have been
made between formaldehyde exposure and nasal carcinoma (Kerns
et al., 1983). Furthermore, the International Agency for Research
on Cancer (IARC, 2006) has classified formaldehyde as a human
carcinogen. One of us (Glen E. Kisby) recently reported that geno-
toxins in cigarette smoke, in which formaldehyde is predominant,
induce various types of DNA damage (single- and double-strand
breaks; DNA-protein crosslinks) in the brains of mice, with coin-
cident changes in the ratio of tau isoforms and phosphorylated
tau (La Maestra et al., 2011). Formaldehyde can alkylate DNA
to form adducts, inhibit the expression of MGMT (which specifi-
cally repairsO6-mG DNA lesions; Grafstrom et al., 1985), crosslink
DNA and protein, and bind to albumin or theN -terminal valine of
hemoglobin. In cycling cells, failure to repair O6-mG lesions leads
to mutations (G:C to A:T) and the activation of cellular pathways
that culminate in tumorigenesis.
Formaldehyde also has poorly understood acute and chronic
neurotoxic effects. Insomnia, memory loss, mood alterations,
nausea, and fatigue have been reported with low airborne
formaldehyde concentrations. Prolonged occupational expo-
sure to formaldehyde is associated with somnolence, headache,
seizures, mood instability, memory, and cognitive deficits. Effects
in controlled animal studies include neurobehavioral changes and
neurotoxicity (learning and memory deficits). Levels of superox-
ide dismustase-1 (which is mutated in some cases of dominantly
inherited ALS) and glutathione peroxidase decreased significantly
in the prefrontal cortex of rats treated parenterally with formalde-
hyde (National Toxicology Program, 2010). Other information
links formaldehyde with neurodegenerative diseases related to
ALS-PDC, but definitive evidence is lacking, as summarized below.
Amyotrophic lateral sclerosis
Exposure to cigarette smoke, of which formaldehyde is the major
contaminant, has been strongly linked to ALS risk in two large
epidemiological studies (Weisskopf et al., 2005; Gallo et al., 2009).
Both found significant trends with smoking duration, with pro-
longed and current smoking increasing ALS risk by two- to three-
fold. Time since smoking cessation was associated with a decreased
risk for ALS relative to those who continued smoking. Gallo et al.
(2009) pinpointed formaldehyde as the most likely culprit in cig-
arette smoke, but direct evidence is lacking. Formaldehyde was
also singled out for further research in a large prospective study
of chemical exposures and ALS, which found strongly signifi-
cant dose-response relationships with increasing years of smoking
exposure (Weisskopf et al., 2005, 2010).
Alzheimer disease
Chinese investigators have explored the status of formaldehyde in
AD; they report that formaldehyde levels are increased in 20–40%
of patients with senile dementia (He et al., 2010). These investi-
gators found that human endogenous levels of formaldehyde are
maintained at a low concentration (0.01–008 mmol/l blood) under
physiological conditions, with concentrations increasing during
aging (>65 years). Importantly, urine formaldehyde concentra-
tions of normal elderly volunteers are significantly lower than
those of elderly patients with AD, and the elevated urinary levels
of formaldehyde are inversely correlated with Mini Mental State
Examination (MMSE) scores and hippocampal formaldehyde
concentrations in AD patients (He et al., 2010; Tong et al., 2011).
A correlation between memory loss and brain tissue formalde-
hyde levels was also observed in wild-type mice treated with
formaldehyde (He et al., 2010; Tong et al., 2011). Taken in con-
cert, these data suggest that formaldehyde may have a role in
AD.
Parkinsonism
Chemicals that induce parkinsonism in humans and/or ani-
mals include: methanol, which is oxidized to formaldehyde;
methylphenyltetrahydropyridine, which is formed from formalde-
hyde, methylamine, andα-methylstyrene; rotenone, which inhibits
mitochondrial formaldehyde oxidation, and cycad flour, which
contain formaldehyde-forming neurotoxins (Shen et al., 2010).
That methanol intoxication can precipitate parkinsonism is
long recognized, and a dozen reports describe cases of l-
DOPA-sensitive and -refractory methanol-induced extrapyrami-
dal disease (and one case of multiple system atrophy) over the
past 40 years. Methanol is produced endogenously by hydrol-
ysis of the methylester bonds of proteins that are methy-
lated by the endogenous methyl donor S-adenosylmethione
(SAM). SAM increases formation of methanol, formaldehyde,
and formic acid in striatal homogenates, and formaldehyde
is more toxic to neurons than glial cells. Farnesyl-l-cysteine
analogs, which inhibit SAM methylation, block parkinsonian
signs (tremor, rigidity, abnormal posture, and hypokinesia)
when SAM is injected into the rat brain. Lee et al. (2008)
proposed that a SAM-mediated increase in formaldehyde has
a possible role in PD-like neuronal damage and the aging
process.
SYSTEMS BIOLOGY OF FORMALDEHYDE IN NON-NEURAL CELLS
The Fry laboratory has recently investigated whether formalde-
hyde exposure disrupts miRNA expression levels within lung cells
(Rager et al., 2011). Human A549 lung epithelial cells were exposed
to formaldehyde (1 ppm) using an in vitro exposure system that
physically replicates in vivo human lung gas exposures (Bakand
et al., 2005). Upon exposure to formaldehyde, the lung epithe-
lial cells showed decreased expression in 89 of 534 miRNAs that
were measured using human miRNA microarrays (version 1).
All of the modulated miRNAs were downregulated by formalde-
hyde exposure. This general trend of miRNA down-regulation
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has been observed in rat lung cells exposed to cigarette smoke
(Izzotti et al., 2009), as well as in multiple tumor cell types,
including lung cancer, breast cancer, and leukemia (Lu et al.,
2005).
A detailed analysis was made on the four most significantly
down-regulated miRNAs, namely miR-33, miR-330, miR-181a,
and miR-10b, as determined through microarray analysis and
qRT-PCR. These miRNAs have been studied to some extent,
and knowledge about their regulation and association to dis-
ease is growing. For example, the expression level of miR-33 is
decreased in tissues from patients with lung carcinoma (Yanai-
hara et al., 2006). In addition, miR-330 expression levels are
reduced in human prostate cancer cells when compared with non-
tumorigenic prostate cells (Lee et al., 2009). Furthermore, miR-330
has been suggested to act as a tumor suppressor by regulating
apoptosis of cancer cells (Lee et al., 2009). In addition, miR-10b
shows altered expression levels within breast cancer tissue and is
one of the most consistently dysregulated miRNAs able to predict
tumor classification (Iorio et al., 2005; Ma et al., 2007). These find-
ings suggest that miR-33, miR-330, and miR-10b may influence
cellular disease state, specifically related to cancer. Formaldehyde
exposure also altered the expression level of miR-181a, which has
known associations with leukemogenesis (Marcucci et al., 2009).
The specific link between formaldehyde exposure and leukemia
is currently debated, as numerous epidemiological studies show
evidence for possible association with this disease (Pinkerton
et al., 2004; Zhang et al., 2010b), as well as against it (Marsh
and Youk, 2004; Bachand et al., 2010). Nevertheless, the dys-
regulation of miR-181a upon exposure to formaldehyde is of
interest.
A systems-biology approach was used to understand the poten-
tial biological implications of the miRNA expression changes
induced in lung cells by acute formaldehyde exposure. A stringent
computational matching approach was used to identify predicted
mRNA targets for miR-33, miR-330, miR-181a, and miR-10b.
The identified mRNA targets were used to construct molecular
networks and were analyzed for their known involvement in sig-
naling pathways and biological functions. The identified networks
showed enrichment for various canonical pathways, including NF-
κB and interleukin-8 (IL-8) signaling. Although very few predicted
targets overlapped among the four miRNAs,proteins involved with
cancer mechanisms (including that of the NF-κB pathway) were
found within the miRNA target networks. Importantly, NF-κB
has clear links to inflammation and cancer development (Karin
and Greten, 2005; Schmid and Birbach, 2008). Also related to
inflammation, IL-8-related signaling molecules were present in the
miRNA target networks. Previous studies have shown IL-8 release
in lungs cells representing an inflammatory response after expo-
sure to other air pollutants (Jaspers et al., 1997; Sexton et al., 2004).
In addition, investigations have shown increased IL-8 levels in
lungs of patients with diseases such as acute lung injury (McClin-
tock et al., 2008), adult respiratory distress syndrome (Jorens et al.,
1992), and asthma (Bloemen et al., 2007). Inflammation is a recog-
nized formaldehyde-induced response, as formaldehyde is known
to irritate the respiratory system (Tuthill, 1984) and increase asth-
matic response (Wieslander et al., 1997; Rumchev et al., 2002).
The new findings suggest that the canonical pathways associated
with formaldehyde-induced miRNA alterations may impact the
regulation of biological pathways associated with various disease
states, including cancer and inflammation (Rager et al., 2011).
There is also a vast literature on the possible pathogenic role
of inflammation in neurodegenerative diseases, including ALS,
PD, AD, and ALS-PD, the subject of the present paper (McGeer
and McGeer, 1998, 2001; Lewis et al., 2012; Tufekci et al., 2012).
A neuroinflammatory response was suggested by the presence
of transcriptional changes in extracellular-matrix-receptor inter-
action (four genes upregulated, one gene downregulated) and
cytokine–cytokine receptor interaction (three genes upregulated,
two genes downregulated) in the brains of adult Mgmt−/− mice
treated 6 months earlier with a single dose of MAM (Kisby et al.,
2011b).
The data obtained with the lung epithelial cells were compared
with those of an existing genomics database (e.g., mRNA) from
a study that evaluated human lung cells exposed to formalde-
hyde (Li et al., 2007). Using the predicted targets in the most
significant miRNA networks, the following genes showed overlap:
BDNF, BMPR2, CACNA1C, CSNK1D, HMGA2, HSF2, HSPH1,
and PIM1. These genes have been shown to play a role in var-
ious diseases. For example, BDNF modulates neurogenesis after
injury to the central nervous system (Ming and Song, 2005).
CSNK1D, or casein kinase 1δ, is upregulated in breast can-
cer tissue (Abba et al., 2007). HMGA2, or high mobility group
AT-hook 2, is oncogenic in many cells, including lung carci-
noma cells, and is regulated by the tumor-suppressive miRNA
let-7 (Lee and Dutta, 2007). Lastly, the serine-threonine pro-
tein kinase gene PIM1, or Pim-1 oncogene, is found at increased
levels within prostate cancer tissue (Dhanasekaran et al., 2001).
Network analysis of all formaldehyde-responsive genes identified
through the Li et al. (2007) study revealed significant associa-
tions with cancer, inflammation, and endocrine system regulation,
which also overlap with the findings of Rager et al. (2011). These
genes are therefore linked with formaldehyde-induced changes
in miRNA abundance as well as mRNA alterations, and they
are related to a diverse range of cellular responses including
tumorigenesis.
In summary, the new data provide evidence of a potential
mechanism that may underlie the cellular effects induced by
formaldehyde, namely an alteration in miRNA expression. The
set of 89 miRNAs was changed in human lung cells exposed
to formaldehyde. Mapping the most significantly changed miR-
NAs to their predicted mRNA targets and their network interac-
tomes within the cell revealed the association of formaldehyde
exposure to inflammatory response pathways. Future research
will investigate whether the expression levels of these miRNAs
may serve as potential biomarkers of formaldehyde exposure
in humans. Such biomarkers can be utilized to better monitor
human exposure to environmental toxicants and their related
health effects. Based on these findings, it was suggested that miR-
NAs likely play an important role in regulating formaldehyde-
induced gene expression and may represent a possible link
between exposure and disease. Whether these results can be
extrapolated to tissues other than lung, notably to brain tissue,
is unknown. However, since formaldehyde is also a metabolite
of MAM (and l-BMAA), it is of interest to determine if the
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modulation of miRNAs by formaldehyde in the lung can be related
to brain transcriptional changes induced by systemic exposure to
MAM.
CORRELATION OF miRNAs IN FORMALDEHYDE, MAM, CANCER, AND
NEURODEGENERATION
To identify miRNAs that may mediate MAM-associated gene
expression, we examined all genes that were altered in expression
in the most significant brain expression network published in our
earlier study of transcriptional changes induced in adult wild-type
mice vs. Mgmt−/− (see Figure 3 from Kisby et al., 2011a). All genes
whose expression was altered by MAM vs. vehicle in the Mgmt−/−
mice were examined for miRNA seed matches. The miRNA data-
base (miRDB, www.mirdb.org) was used to predict miRNAs with
seed regions that match the base pair sequences of the mRNAs
within their 3′-UTR (Wang, 2008; Wang and El Naqa, 2008). There
were 18 genes for which one or more miRNAs was identified. A
comparison of all 89 formaldehyde-modulated miRNAs in human
lung epithelial cells (Rager et al., 2011) with the miRNAs predicted
here to regulate genes in the brains of MAM-treated Mgmt−/−
mice show overlap of 6 miRNAs: miR-107, miR-152, miR-17-5p,
miR-181d, and miR-454-3p. MiR-107 promotes tumor progres-
sion and is linked to AD (Chen et al., 2011; Augustin et al., 2012).
MiR-152 inhibits proliferation of ovarian cancer cell lines and is
regulated in axon guidance (Liu et al., 2012; Zhou et al., 2012).
MiR-17-5p and miR-181d, which are downregulated in
formaldehyde-treated human lung epithelial cells, were predicted
to regulate the greatest number of genes in the brains of MAM-
treated Mgmt−/− mice (Figure 3). MiR-181d, which regulates the
three genes shown in Figure 3, down-regulates MGMT mRNA and
protein expression in glioblastoma cells (Zhang et al., 2012b), is
involved in MAPK signaling in pancreatic cancer cells (Ikeda et al.,
2012), and is upregulated by hepatic transforming growth fac-
tor beta (TGFβ) in promoting hepatocarcinogenesis (Wang et al.,
2010). MiR-17-5p targets tumor protein P53-induced nuclear pro-
tein 1 (TP53INP1), which suppresses cell growth and promotes
apoptosis of cervical cancer cells (Wei et al., 2012). Behrens et al.
(2009) have noted that whereas reduced P53 expression arising
from mutations may lead to uncontrolled cell proliferation, as
in colorectal cancer, osteosarcoma, and other tumors, increased
P53 expression may activate pathways leading to cell death, such
as occurs in AD. MiR-17-5p also has tumor-suppressing activity
in hepatocellular, gastric, pancreatic, breast, and cervical cancer
(Hossain et al., 2006; Yu et al., 2010; Chen et al., 2012; Wang et al.,
2012) and is also thought to be involved in the regulation of APP
expression (Hébert et al., 2009).
SUMMARY AND CONCLUSION
Understanding the etiology and pathogenesis of western Pacific
ALS-PDC is expected to illuminate related neurodegenerative dis-
orders, including ALS and AD. ALS-PDC is predominantly or
exclusively an environmental disorder of unknown causation but
strongly associated with prior exposure to cycad seed, which con-
tains neurotoxic compounds (cycasin/l-BMAA) that are metabo-
lized to formaldehyde, a human carcinogen. While highly plausi-
ble, a cause-effect relationship between these agents and ALS-PDC
has yet to be established.
FIGURE 3 | Formaldehyde-responsive miRNAs predicted to modulate
MAM-associated genes in the brains ofMgmt−/− mice.These include
miR-17-5p and miR-181d, which regulate genes involved in tumor
suppression, DNA repair, amyloid deposition, and glutamatergic and
dopaminergic neurotransmission. MiR-17-5p regulates the expression of
EPHA4, GNPDA2, and TXNIP. There is a large brain-related literature on the
gene encoding ephrin type-A receptor 4 (EPHA4) which, in the
hippocampus, is located in the neuropil layers of CA1, CA3, and dentate
gyrus. EPHA4 is involved in axonal development, maturation, targeting, and
synapse formation (Tremblay et al., 2007; Clifford et al., 2011). Inhibition of
EPHA4 signaling reduces apoptosis in hippocampal CA1 neurons and is
involved in the γ-secretase pathway, which processes APP to the
extracellular amyloid deposits that characterize AD, ALS-PDC, and other
tauopathies (Inoue et al., 2009). EphA4 and EphB2 receptors were reduced
in the hippocampus before the development of impaired object recognition
and spatial memory in an AD mouse model of cognitive decline that
overexpresses human APP protein (Simón et al., 2009). Literature on the
gene coding for glucosamine-6-phosphate deaminase 2
(2-amino-2-deoxy-d-glucose 6-phosphate; GNPDA2) is primarily related to
obesity; the gene is downregulated in the hypothalamus in rats on a high
fat diet (Gutierrez-Aguilar et al., 2012). The gene encoding
thioredoxin-interacting protein (TXNIP ) is a molecular nutrient sensor
important in the regulation of energy metabolism and also involved in
obesity (Blouet and Schwartz, 2011). Blockade of the NMDA receptor
upregulates TXNIPin vivo and in vitro, where it binds thioredoxin and
promotes vulnerability to oxidative damage (Martel et al., 2009).
Transcriptional expression of both TXNIP and TP53 is upregulated in
Cockayne syndrome, a human premature aging and dementing disorder
(without amyloid deposition) associated with neurological and
developmental abnormalities, and caused by mutations mainly in the CS
group B gene (ERCC6, excision repair cross-complementing rodent repair
deficiency 6; de Sousa Andrade et al., 2012). MiR-181d regulates the
expression of CAMK2D, GRM5, NTS, and RFC1. The gene coding for DNA
replication factor-1 (RFC1) is involved in DNA replication and repair, which
would be expected following either MAM- or formaldehyde-induced DNA
lesions. Neurotensin (NT) is a brain and gastrointestinal peptide that acts on
G-coupled and transmembrane receptors that modulate dopaminergic
transmission in brain pathways, notably the nigrostriatal pathway that
degenerates in PD. Interactions may exist between NT receptor subtype 1
(NTS1) and dopamine D2 or NMDA receptors, such that NT-induced
amplification of the latter may be involved in neurodegeneration (Tanganelli
et al., 2012). GRM5 codes for the metabotropic glutamate receptor 5, one
of the neuronal synaptic receptors that responds to the brain’s major
excitatory transmitter glutamate. This activates a G-protein-coupled
response that activates a phosphatidylinositol-calcium second messenger
system and generates a calcium-activated chloride current. GRM5 is
upregulated following repeated exposure to glutamate in vitro (Kawaai
et al., 2010), downregulated in schizophrenia (Choi et al., 2009) and most
probably involved in a host of degenerative disorders. MiR-181d also
regulates the expression of calcium/calmodulin-dependent protein kinase II
delta (CAMK2D).
The mechanisms underlying the neurotoxic and carcinogenic
action of MAM are related and specifically tied to the modulation
of signaling pathways apparently triggered by unrepaired DNA
damage. Whereas MAM-induced perturbation of those pathways
leads to uncontrolled division in cycling cells, in brain tissue
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FIGURE 4 | Common pathways underlying cancer and
neurodegenerative diseases that are mediated by miRNAs.
(containing post-mitotic neurons), the primary outcome is linked
to neurological diseases and perhaps to ALS-PDC, with which
the MAM-glycone (cycasin) is strongly associated in epidemio-
logical studies. Whether this is mediated by MAM directly or by
formaldehyde is unknown, but clearly the mechanisms underly-
ing MAM murine neurotoxicity and carcinogenicity are related
(Figure 4).
Selected miRNAs appear to stand at the crossroads between
the toxic actions of MAM and formaldehyde. Direct evidence
exists to implicate a number of miRNAs in the acute actions
of formaldehyde in non-neural (lung) cells. Formaldehyde-
responsive miRNAs predicted to modulate MAM-associated genes
in mouse brains lacking MGMT include miR-17-5p and miR-
18d, which regulate genes involved in tumor suppression, DNA
repair, amyloid deposition, and glutamatergic and dopaminer-
gic neurotransmission. However, direct evidence for the involve-
ment of specific miRNAs in MAM-induced neurotoxicity has
yet to be demonstrated. This conclusion notwithstanding, there
is a provocative association between top KEGG pathways in
the brains of mice exposed to MAM and in human cancers,
with suspicion falling heavily on a prominent role for at least
one miRNA, namely miR-1. However, miRNAs are but one of
at least three known mechanisms of epigenetic regulation, and
there is no information on the possibility that MAM modu-
lates brain gene expression via cytosine methylation or histone
modification.
The ALS-PDC-associated cycad genotoxins MAM and cycasin
are but two among a large number of chemicals, including a
variety of food additives, food components, environmental conta-
minants,N -nitroso compounds, rodent carcinogens, and antineo-
plastic agents that have been evaluated in non-human primates for
their long-term carcinogenic activity (Thorgeirsson et al., 1994).
Treatment of primates with cycasin or MAM induced primarily
HCC, but also renal, esophageal, and intestinal adenocarcino-
mas (Sieber et al., 1980; Adamson, 1989). Emerging evidence
indicates that miRNA dysregulation plays a key role in HCC
by promoting a number of cancer-inducing cell-signaling path-
ways (Law and Wong, 2011; Negrini et al., 2011). The aberrant
activation of the Wnt/β-catenin signaling pathway is reportedly
a significant contributor in HCC (Takigawa and Brown, 2008;
Nambotin et al., 2011; Nejak-Bowen and Monga, 2011), a promi-
nent pathway that was also perturbed by MAM in the rodent
brain (Kisby et al., 2011a). Dysregulation of Wnt/β-catenin sig-
naling is also frequently observed as an early event in the AOM-
induced (MAM-mediated) rodent model of colon cancer (Taki-
hashi and Wakabayashi, 2004; see Figure 2). Thus, HCC, colon,
and other carcinomas induced by MAM in non-human primates
might involve the activation of downstream cell-signaling path-
ways by associated miRNAs. While MAM-induced activation of
the Wnt/β-catenin pathway leads to uncontrolled cell proliferation
in the AOM model of colon cancer, suppression of this path-
way in the brain may promote cell death. Boonen et al. (2009)
propose that disrupting the tightly regulated brain Wnt signaling
pathway may constitute a key pathological event in AD. They pro-
pose that amyloid-beta (Aβ), a key protein in the senile plaques
of AD, may down-regulate the Wnt/β-catenin pathway, thereby
upregulating GSK3β and its subsequent hyperphosphorylation of
tau, linking Aβ and the neurofibrillary pathology characteristic
of AD and ALS-PDC. This is consistent with recent data showing
that GSK3β, GSK3α, tau oligomers, and phosphorylated and trun-
cated forms of tau are elevated in a mouse model of AD (Kisby
et al., 2011c). Others have shown that inhibition of GSKβ increases
mouse brain IGF-1 (Bolós et al., 2010), which in turn promotes
Aβ production (Araki et al., 2009; De La Monte, 2009). Tran-
scriptome analysis of enzymes involved in tau phosphorylation
point to the involvement of extracellular signal-regulated kinase 1
(ERK1), the gene that was perturbed in a DNA-damage-anchored
manner in the brains of Mgmt−/− mice both days and 6 months
after a single systemic dose of MAM; ERK1 protein was signif-
icantly increased at the later timepoint, as was fodrin cleavage,
which indicates the activation of caspase-3 (Kisby et al., 2011b), an
enzyme with an important role in cleaving tau (Rohn et al., 2002).
Tumor-suppressor miR-16 (downregulated in some cancers) and
miR-132 (which is methylation-silenced in prostate cancer) have
been identified as putative endogenous modulators of neuronal
tau phosphorylation and tau exon 10 splicing, respectively (Bot-
toni et al., 2005; Hébert et al., 2010; Formosa et al., 2012; Rivas
et al., 2012).
In conclusion, murine brain signaling pathways modulated
by MAM and linked to human neurological disease over-
lap with those associated with MAM-induced colon cancer.
The two disease phenotypes, cancer and neurodegeneration,
are mechanistically related; their differential expression may
depend respectively on whether or not (as is the case for
adult neurons) MAM-exposed cells are able to undergo mito-
sis, mutagenesis, and uncontrolled cell proliferation (Kisby
et al., 2011a). If the foregoing is true, then the lessons
learned from cycad-associated ALS-PDC, a prototypical neu-
rodegenerative disorder, should be applied to related diseases of
old age.
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